EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

Claire Gallois iD, Qian Shi iD, Jeffrey P Meyers, Timothy Iveson iD, Steven R Alberts iD, Aimery de Gramont iD, Alberto F Sobrero iD, Daniel G Haller iD, Eiji Oki iD, Anthony Frank Shields iD, Richard M Goldberg iD, Rachel Kerr und 12 weitere

Journal of Clinical Oncology · 01.02.2023 · 41 (4) · 803-815

DOI: 10.1200/jco.21.02726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.02.2023. Verfasst von Claire Gallois und 23 weiteren Autor:innen. Beteiligte Einrichtung: Paris-Cité University, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France. Hauptthemen laut MEDLINE: Colonic Neoplasms, Oxaliplatin. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) could worsen the prognosis. MATERIALS AND METHODS We studied the prognostic impact of ETD and EOD in patients with stage III CC from the ACCENT/IDEA databases, where patients were planned to receive 6 months of infusional fluorouracil, leucovorin, and oxaliplatin or capecitabine plus oxaliplatin. ETD was defined as discontinuation of treatment and EOD as discontinuation of oxaliplatin only before patients had received a maximum of 75% of planned cycles. Association between ETD/EOD and overall survival and disease-free survival (DFS) were assessed by Cox models adjusted for established prognostic factors. RESULTS Analysis of ETD and EOD included 10,447 (20.9% with ETD) and 7,243 (18.8% with EOD) patients, respectively. Compared with patients without ETD or EOD, patients with ETD or EOD were statistically more likely to be women, with Eastern Cooperative Oncology Group performance status ≥ 1, and for ETD, older with a lower body mass index. In multivariable analyses, ETD was associated with a decrease in disease-free survival and overall survival (hazard ratio [HR], 1.61, P < .001 and HR, 1.73, P < .001), which was not the case for EOD (HR, 1.07, P = .3 and HR, 1.13, P = .1). However, patients who received < 50% of the planned cycles of oxaliplatin had poorer outcomes. CONCLUSION In patients treated with 6 months of oxaliplatin-based chemotherapy for stage III CC, ETD was associated with poorer oncologic outcomes. However, this was not the case for EOD. These data favor discontinuing oxaliplatin while continuing fluoropyrimidine in individuals with significant neurotoxicity having received > 50% of the planned 6-month chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsOxaliplatinFemaleHumansMaleAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFluorouracilLeucovorinNeoplasm StagingPrognosis

Substanzen

FluorouracilLeucovorinOxaliplatin

Autor:innen und Institutionen

  • Paris-Cité University, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France.
  • Department of Health Science Research, Mayo Clinic, Rochester, MN.
  • Department of Medical Oncology, University of Southampton, Southampton, United Kingdom.
  • Department of Oncology, Mayo Clinic, Rochester, MN.
  • Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
  • Medical Oncology, IRCCS San Martino IST, Genoa, Italy.

ORCID-Profile: Claire Gallois, Qian Shi, Timothy Iveson, Steven R Alberts, Aimery de Gramont, Alberto F Sobrero, Daniel G Haller, Eiji Oki, Anthony Frank Shields, Richard M Goldberg, Sara Lonardi, Greg Yothers, Ioannis Boukovinas, Frank A Sinicrope, Takayuki Yoshino, Jeffrey A Meyerhardt, Thierry André, Julien Taieb

Förderung

  • Cancer Research UK

Zitieren

APA

Gallois, C., Shi, Q., Meyers, J. P., Iveson, T., Alberts, S. R., de Gramont, A., Sobrero, A. F., Haller, D. G., Oki, E., Shields, A. F., Goldberg, R. M., Kerr, R., Lonardi, S., Yothers, G., Kelly, C., Boukovinas, I., Labianca, R., Sinicrope, F. A., Souglakos, I., …, & Taieb, J. (2023). Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. Journal of Clinical Oncology, 41(4), 803-815. https://doi.org/10.1200/jco.21.02726

Vancouver

Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, et al. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. Journal of Clinical Oncology. 2023;41(4):803-815. doi:10.1200/jco.21.02726

BibTeX
@article{Gallois2023,
  author = {Gallois, Claire and Shi, Qian and Meyers, Jeffrey P and Iveson, Timothy and Alberts, Steven R and de Gramont, Aimery and Sobrero, Alberto F and Haller, Daniel G and Oki, Eiji and Shields, Anthony Frank and Goldberg, Richard M and Kerr, Rachel and Lonardi, Sara and Yothers, Greg and Kelly, Caroline and Boukovinas, Ioannis and Labianca, Roberto and Sinicrope, Frank A and Souglakos, Ioannis and Yoshino, Takayuki and Meyerhardt, Jeffrey A and André, Thierry and Papamichael, Demetris and Taieb, Julien},
  title = {Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {4},
  pages = {803--815},
  doi = {10.1200/jco.21.02726}
}
Kostenlos starten →